Multicentric study on the effect of an alpha glucosidase inhibitor in the treatment of non insulin dependent diabetes;Experiencia clínica con un inhibidor de la alfa glucosidasa (acarbosa) en el tratamiento de la diabetes no insulinodependiente. Estudio Multicéntrico

Revista Medica de Chile

Volumn 125, Issue 8, 1997, Pages 856-862

  García De Los Ríos A, Manuel ^a   Mujica E, Verónica ^b   Muñoz S, Silvana ^b   Durruty A, Pilar ^b   Larenas Y, Gladys ^b   López B, M Isabel ^b   Kuzmanic V, Andrés ^b   Pérez C, Jaime ^b   Flaskamp VF, Renate ^b   Cumsille G, Francisco ^b  

^a Vitacura 5560 Depto 152   (Chile)

^b NONE

Author keywords

Diabetes mellitus; Enzyme inhibitors; Glucosidases; Non insulin dependent; Sulphonylureas

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; ENZYME INHIBITOR; SULFONYLUREA DERIVATIVE; TRISACCHARIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG ANTAGONISM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY;

ACARBOSE; ADULT; AGED; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; TRISACCHARIDES;

EID: 0031197190     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. PHILLIPS PJ. Role of diet and exercise in management of NIDDM. In: HD Breidahl ed. Type II Diabetes. NIDDM. Current Status. Excerpta Medica; Amsterdam 1986; 6-10.
2. CONSENSO ASOCIACION LATINOAMERICANA DE DIABETES. Prevención, Control y Tratamiento de la Diabetes Mellitus no Insulinodependiente. Eds. Mayo. Argentina. 1995.
3. WOLFFENBUTTEL BH, VAN HAEFTEN TW. Prevention of complications in non-insulin-dependent diabetes mellitus. Drugs 1995; 50: 263-88.
4. ALBERTI KGMM, GRIES F. European NIDDM policy group: Management of non-insulin dependent diabetes mellitus in Europe: a consensus view. Diabetic Med 1988; 5: 275-81.
5. THE DIABETES CONTROL AND COMPLICATIONS TRIAL. Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
6. BISCHOFF H. Pharmacology of alpha-glucosidase inhibition. Eur J Clin Invest 1994; 24 (Suppl 3): 3-10.
7. CLISSOLD SP, EDWARDS C. Acarbose, a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1988; 13 (Suppl 3): 47-52.
8. HANEFELD M, FISCHER S, SCHULZE J ET AL. Therapeutic potential of acarbose as firts-line drug in NIDDM insuficiently treated with diet alone. Diabetes Care 1991; 14: 732-7.
9. CONIFF RF, SHAPIRO JA, ROBBINS D ET AL. Reductions of glycosylated hemoglobin and post prandial hyperglycemia by acarbose in patients with NIDDM. A placebo controlled dose-comparison study. Diabetes Care 1995; 18: 817-24.
10. GOLDSTEIN DE, LITTLE RR, WIEDMEYER HM ET AL. Glycated hemoglobin: Methodologies and clinical applications. Clin Chem 1986; 32: B64-B70.
11. RUIZ M, MATRONE A, ALVARIÑES J Y COLS. Estudio multicéntrico para determinar la eficacia y tolerancia de Acarbosa (Bay G 5421) en pacientes DMNID: Pren Med Argent 1996; 83: 392-8.
12. GONZALEZ D, CORREA A, MARES G, CARDEÑOSA O. Acarbosa: Nueva arma terapéutica en el manejo de la diabetes mellitus. Rev de la ALAD 1996; 4: 22-8.
13. JOSSE RG. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trail. Diabetes Res Clin Pract 1995; 28 (Suppl): S167-S72.
14. CONIFF RF, SHAPIRO JA, SEATON TB, HOOGWERF BJ, HUNT JA. A double blind placebo controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin requiring type II diabetes. Diabetes Care 1995; 18: 928-32.
15. HOFFMAN J, SPENGLER M. Efficacy of 24 week monotherapy with acarbosa, glibenclamide or placebo in NIDDM patients. The Essen Study. Diabetes Care 1994; 17: 561-6.
16. LEHOVITZ HE. Oral antidiabetic agents: the emergence of alphaglucosidase inhibitors. Drugs 1992; 44: 21-8.
17. REAVEN G, LARDINOIS C, GREENFIELD M Y COLS. Effect of Acarbose on carbohydrate and lipid metabolism in NIDD patients poorly controlled by sulfonylureas. Diabetes Care 1990; 13 (Suppl 3): 32-6.
18. KEEN H. Glucomodulation: a new therapeutic approach. Pract Diabetes 1993; 10 (Suppl): S55-S9.
19. CHIASSON JL, JOSSE R, HUNT J Y COLS. The efficacy of Acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928-35.
20. SINCLAIR AJ. Rational approaches to the treatment of patients with non-insulin-dependent diabetes mellitus (NIDDM). Pract Diabetes 1993; 10 (Suppl): S15-S20.
21. LEBOVITZ HE: Oral hypoglycemic agents. En: Rifkin H, Porte D. eds: Ellenberg and Rifkin's. Diabetes Mellitus. Theory and Practice. 4 ed. New York: American Elsevier Science Publishing Co Inc 1990; pp 554-76.
22. GROOP LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-54.
23. BAILEY CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-72.
24. BAYRAKTAR M, VAN THIEL DH, ADALAR N. A comparison of Acarbose versus Metformin as an adjuvant therapy in sulfonylurea-treated NIDD patients. Diabetes Care 1996; 19: 252-4.